In a phase 1/2a trial in 80 participants aged 20-47, a trivalent Salmonella conjugate vaccine (Typhi, Typhimurium, Enteritidis) at three strengths vs placebo was well tolerated, with 85-100% antibody and ASC response rates and no significant difference between formulations.
RCTn = 80
Chen et al. Safety and Immunogenicity of a Trivalent Salmonella Conjugate Vaccine to S. Typhi, S. Typhimurium, and S. Enteritidis